Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Subcutaneous on par with IV pembrolizumab for NSCLC
Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.
Subcutaneous on par with IV pembrolizumab for NSCLC
17 Jul 2025
Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD
Intranasal esketamine, administered at two fixed doses as monotherapy for treatment-resistant depression (TRD), has demonstrated robust and rapid efficacy in a phase IV double-blind, placebo-controlled randomized trial.
Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD
17 Jul 2025
RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals
A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.